A phase I study (NCT02476123) showed that combining nivolumab, with mogamulizumab (a Treg-depleting anti-CCR4 antibody) provided an acceptable safety profile and anti-tumor activity, with populations of effector Tregs reduced and CD8+ T cells in TILs increased [121]. The gene discussed is CCR4; the disease is neoplasm.